AI slashes drug discovery time in China to under a year
A single AI platform in China has just shrunk the early phase of drug discovery from years to months—challenging long-held assumptions about how new medicines are born. Insilico Medicine’s generative AI pipeline is producing preclinical drug candidates in as little as nine months, with a typical cycle of about 13 months, compared to the conventional 4.5-year timeline. The Hong Kong-listed company says its fastest programme reached candidate nomination in just nine months, while most programmes land in the 12-to-18-month window after testing between 60 and 200 molecules.
The AI-enabled workflow behind the speed-up
Insilico’s platform integrates generative AI to pinpoint biological targets, design candidate molecules, and triage compounds for physical testing. Human researchers then review AI outputs, run lab experiments to confirm activity and properties, and validate the best molecules before scale-up. Crucially, the company has not disclosed a head-to-head comparison with non-AI programmes, but it reports that its AI-guided process allows teams to reach candidate nomination after testing fewer synthesised molecules. Since 2021, Insilico has generated 31 preclinical candidates, and 13 have cleared investigational new drug applications, clearing the way for human studies.
China’s infrastructure as a catalyst
Much of the experimental validation and scale-up happens at Insilico’s Shanghai facility, which features automated sampling and compound screening. Meanwhile, AI model development and evaluation occur in Montreal and Abu Dhabi. According to CEO Alex Zhavoronkov, China’s research infrastructure, lower operating costs, and streamlined regulatory environment account for part of the timeline compression. He estimates that labs in China can cut roughly two years off traditional candidate-development timelines. China’s push beyond generic ingredients into novel drug development is gaining traction, with international drugmakers increasingly tapping local labs, CROs, and clinical-trial centres. A Pfizer executive cited clinical development in China as three times faster and about half the cost of equivalent work in Europe.
Why it matters
The shift signals that AI is no longer a laboratory curiosity but a practical engine for early-stage drug discovery, especially where cost and speed are decisive. For pharma executives, it means the competitive bar is rising: timelines once measured in years are now negotiable in months, and China’s regulatory fast-track for innovative drugs adds urgency. For patients, shorter candidate timelines could ultimately translate into earlier access to new treatments, though the full journey to market still hinges on clinical trials and regulatory reviews.
Source: AI News. AI-assisted editorial synthesis — TechnoExpress.